CRIS Current Research Information System

LANZA, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 8.813
NA - Nord America 3.957
EU - Europa 2.445
SA - Sud America 716
AF - Africa 171
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 3
Totale 16.114
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.806
CN - Cina 2.471
SG - Singapore 2.408
VN - Vietnam 2.060
IT - Italia 940
HK - Hong Kong 706
BR - Brasile 537
KR - Corea 384
DE - Germania 257
GB - Regno Unito 249
IN - India 201
FR - Francia 172
JP - Giappone 165
NL - Olanda 146
SE - Svezia 132
FI - Finlandia 117
AR - Argentina 85
CA - Canada 78
RU - Federazione Russa 78
IE - Irlanda 74
PH - Filippine 56
BD - Bangladesh 52
UA - Ucraina 52
ID - Indonesia 48
MX - Messico 47
TH - Thailandia 43
CH - Svizzera 41
CI - Costa d'Avorio 37
IQ - Iraq 37
ZA - Sudafrica 37
BG - Bulgaria 35
ES - Italia 33
TR - Turchia 30
TW - Taiwan 30
PL - Polonia 26
EC - Ecuador 21
PK - Pakistan 21
JO - Giordania 19
UZ - Uzbekistan 19
CL - Cile 17
EE - Estonia 17
TG - Togo 17
AT - Austria 16
PY - Paraguay 16
SA - Arabia Saudita 15
VE - Venezuela 14
NG - Nigeria 13
CO - Colombia 12
MA - Marocco 12
SC - Seychelles 11
KE - Kenya 10
LT - Lituania 10
AE - Emirati Arabi Uniti 9
TN - Tunisia 9
AU - Australia 8
BE - Belgio 8
GR - Grecia 7
JM - Giamaica 7
EG - Egitto 6
KZ - Kazakistan 6
MY - Malesia 6
UY - Uruguay 6
ET - Etiopia 5
NP - Nepal 5
CR - Costa Rica 4
OM - Oman 4
PE - Perù 4
RO - Romania 4
SN - Senegal 4
AL - Albania 3
AZ - Azerbaigian 3
BO - Bolivia 3
BY - Bielorussia 3
DK - Danimarca 3
HN - Honduras 3
HR - Croazia 3
MD - Moldavia 3
PR - Porto Rico 3
PS - Palestinian Territory 3
SK - Slovacchia (Repubblica Slovacca) 3
BS - Bahamas 2
CZ - Repubblica Ceca 2
DZ - Algeria 2
GE - Georgia 2
GH - Ghana 2
HU - Ungheria 2
IL - Israele 2
IS - Islanda 2
NI - Nicaragua 2
PA - Panama 2
PT - Portogallo 2
SY - Repubblica araba siriana 2
XK - ???statistics.table.value.countryCode.XK??? 2
AM - Armenia 1
BB - Barbados 1
CG - Congo 1
CW - ???statistics.table.value.countryCode.CW??? 1
CY - Cipro 1
DM - Dominica 1
GY - Guiana 1
Totale 16.098
Salva come PNG Salva come JPEG
Città #
Singapore 1.533
Hefei 807
Hong Kong 669
Ho Chi Minh City 513
Hanoi 449
Beijing 425
San Jose 408
Ashburn 399
Seoul 355
Boardman 295
Santa Clara 259
Fairfield 170
Southend 166
Los Angeles 159
Tokyo 138
Bologna 137
Chandler 105
Dallas 104
New York 98
Da Nang 94
Helsinki 94
Houston 84
Milan 84
Council Bluffs 81
Haiphong 80
Frankfurt am Main 77
Lauterbourg 77
Woodbridge 77
Dublin 74
Bengaluru 72
Seattle 67
Wilmington 67
Ann Arbor 61
Cambridge 52
Buffalo 50
Guangzhou 50
Princeton 46
São Paulo 46
Shanghai 41
Dong Ket 39
Rome 39
Abidjan 37
Chicago 36
Sofia 33
Florence 32
Munich 30
Bern 28
Tongling 28
Jacksonville 27
Biên Hòa 26
Hải Dương 25
Jakarta 25
Redondo Beach 25
Padova 24
Nuremberg 23
Turin 23
Ha Long 21
Nanjing 21
Phoenix 21
Quận Bình Thạnh 21
Amsterdam 20
Baghdad 20
Rio de Janeiro 20
Toronto 20
Zhengzhou 20
Amman 19
Bắc Ninh 19
Changsha 19
Genoa 19
San Francisco 19
Mexico City 18
Tianjin 18
Warsaw 18
Lappeenranta 17
Lomé 17
Naples 17
Tashkent 17
Thái Nguyên 17
Westminster 17
Orem 16
Can Tho 15
Elk Grove Village 15
Hangzhou 15
Montreal 15
Ninh Bình 15
Shenyang 15
Shenzhen 15
Xi'an 15
Jinan 14
Paris 14
Bangkok 13
Bắc Giang 13
Shijiazhuang 13
Điện Bàn 13
Brasília 12
Chennai 12
Denver 12
Forlì 12
Rimini 12
Salt Lake City 12
Totale 9.786
Salva come PNG Salva come JPEG
Nome #
Stem Cells 367
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study 281
A simple method for identifying bone marrow mesenchymal stromal cells with a high immunosuppressive potential. 255
AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia 250
Isolation of stem cell populations with trophic and immunoregulatory functions from human intestinal tissues: potential for cell therapy in inflammatory bowel disease. 238
A decreased positivity for CD90 on human mesenchymal stromal cells (MSCs) is associated with a loss of immunosuppressive activity by MSCs. 236
Cellule staminali. Embrionali, mesenchimali, emopoietiche, intestinali, cardiovascolari, muscolari, nervose e placentari 227
Impact of Pre-Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating Agents 207
A functional role for soluble HLA-G antigens in immune modulation mediated by mesenchymal stromal cells. 188
Umbilical cord blood CD34(+)cell-derived progeny produces human leukocyte antigen-G molecules with immuno-modulatory functions. 187
Uncovering the expression of circPVT1 in the extracellular vesicles of acute myeloid leukemia patients 178
Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia 171
Upfront intensive treatment analysis of the Italian Cohort Study on FLT3‐mutated AML patients (FLAM): The impact of a FLT3 inhibitor addition to standard chemotherapy in the real‐life setting 169
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study 162
Azacitidine Low-Dose Schedule In Low-Risk Myelodysplastic Syndromes. Preliminary Results of a Multicenter Phase II Study 161
Analysis of 339 pregnancies in 181 women with 13 different forms of inherited thrombocytopenia. 157
Description of 18 PNH patients with prevalent GPI‐deficient monocytes. An Italian survey 156
Identification of Novel Potential Predisposing Variants in Familial Acute Myeloid Leukemia 155
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies 154
Azacitidine low-dose schedule in low-risk myelodysplastic syndromes. Clinical results of a multicenter phase II study 148
Multiple Myeloma: The Role of Autologous Stem Cell Transplantation in the Era of Immunotherapy 145
Acute Myeloid Leukemia: Updates on Diagnosis, Treatment and Management 145
Novel insights and therapeutic approaches in secondary AML 144
INO-CD22: A Multi-Center, Real-Life Study on Inotuzumab-Ozogamicin Safety and Effectiveness in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia 143
European Data on Stem Cell Mobilization with Plerixafor in Non-Hodgkin’s Lymphoma, Hodgkin’s Lymphoma and Multiple Myeloma Patients. A Subgroup Analysis of the European Consortium of Stem Cell Mobilization. 141
Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COV 138
Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin 134
Comparative clinical efficacy and safety of biosimilar ABP 959 and eculizumab reference product in patients with paroxysmal nocturnal hemoglobinuria 129
New Horizons in Immunology and Immunotherapy of Acute Leukemias and Related Disorders 125
Five‐Year Real‐World Safety of Inotuzumab Ozogamicin Before Hematopoietic Stem Cell Transplantation in B‐Cell Precursor Acute Lymphoblastic Leukemia 124
Low WT1 Expression Identifies a Subset of Acute Myeloid Leukemia with a Distinct Genotype 124
Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model 122
Vinciamo la vita. Oltre la cura il benessere. Un percorso di lungo periodo nell'alleanza medico paziente-famiglia. 122
CD22 expression in b-cell acute lymphoblastic leukemia: Biological significance and implications for inotuzumab therapy in adults 122
Long-term survival can be achieved in a significant fraction of older patients with core binding factor acute myeloid leukemia treated with intensive chemotherapy 119
Higher BMI is not a barrier to stem cell mobilization with standard doses of plerixafor and G-CSF. 117
Autologous stem cell transplantation (ASCT) for acute myeloid leukemia in patients in first complete remission after one versus two induction courses: A study from the ALWP of the EBMT 116
Long-Term Outcome of Peripheral Blood Autologous Stem Cell Transplantation (AutoSCT) for De Novo Acute Myeloid Leukemia in Patients Achieving First Complete Remission after One Vs Two Induction Courses: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT) 115
Low-Dose Cyclophosphamide versus Intermediate-High-Dose Cyclophosphamide versus Granulocyte Colony-Stimulating Factor Alone for Stem Cell Mobilization in Multiple Myeloma in the Era of Novel Agents: A Multicenter Retrospective Study 114
Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo italianoTrapianto di Midollo Osseo. 113
Pharmacological inhibition of wip1 sensitizes acute myeloid leukemia cells to the mdm2 inhibitor nutlin-3a 113
Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide. 111
Development of adaptive immune effector therapies in solid tumors 109
ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol 107
Results of the 6-Year Follow- up of the Gimema AML1310 Trial: A Risk-Adapted, MRD-Directed Therapy for Young Adults with Newly Diagnosed Acute Myeloid Leukemia 105
PNH clones prevalence study in ph-negative myeloproliferative neoplasms: a multicenter Italian study 104
Efficacy and Safety of Biosimilar Candidate ABP 959 As Compared with Eculizumab Reference Product in Paroxysmal Nocturnal Hemoglobinuria 102
Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a 101
A REGISTRY-BASED, OBSERVATIONAL SAFETY STUDY OF INOTUZUMAB OZOGAMICIN (INO) IN PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PROCEEDING TO HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) 98
null 97
Impact of comorbidities and body mass index on the outcome of polycythemia vera patients 94
Postremission Consolidation by Autologous Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia in First Complete Remission (CR) and Negative Implications for Subsequent Allogeneic HCT in Second CR: A Study by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT) 93
Targeted Therapies and Druggable Genetic Anomalies in Acute Myeloid Leukemia: From Diagnostic Tools to Therapeutic Interventions 93
Alloreactivity: the Janus-face of hematopoietic stem cell transplantation 93
CD34+ cell dose effects on clinical outcomes after T-cell replete haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia using peripheral blood stem cells. A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT) 91
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study 91
The Circular Life of Human CD38: From Basic Science to Clinics and Back 90
Veno-Occlusive Disease Risk and Other Outcomes in Patients with B-Cell Precursor Acute Lymphoblastic Leukemia Who Received Inotuzumab Ozogamicin and Proceeded to Hematopoietic Stem Cell Transplantation: A Registry-Based, Observational Study 90
PNH CLONES PREVALENCE STUDY IN PH-NEGATIVE MYELOPROLIFERATIVE DISORDERS 89
Olutasidenib (FT-2102) in Combination with Azacitidine Induces Durable Complete Remissions in Patients with mIDH1 Acute Myeloid Leukemia 89
RISK-ADAPTED MRD-DIRECTED THERAPY FOR YOUNG ACUTE MYELOID LEUKEMIA ADULTS: 6-YEAR UPDATE OF THE GIMEMA AML1310 TRIAL 89
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies 88
Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study 85
Pivotal Results of SELECT-MDS-1 Phase 3 Study of Tamibarotene with Azacitidine in Newly Diagnosed Higher-Risk MDS 84
Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3 internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation 83
null 81
Lack of efficacy of convalescent plasma in COVID-19 patients with concomitant hematological malignancies: An Italian retrospective study 81
A comparative analysis of biosimilar vs. originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma: a propensity-score weighted multicenter approach 80
A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi 78
The oldest case of lymphoma? Insights from a XIII century fresco 78
null 77
Lenalidomide plus rituximab for the initial treatment of elderly frail patients with DLBCL: the FIL_ReRi Phase 2 Study 77
null 76
Autologous stem cell transplantation for adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. A study by the Acute Leukemia Working Party of the EBMT 71
Expression of the immunoglobulin superfamily cell membrane adhesion molecule Cd146 in acute leukemia 70
Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency 67
Venetoclax plus hypomethylating agents as effective bridge therapy to allogeneic stem cell transplant in relapsed/refractory acute myeloid leukaemia: A subanalysis of the AVALON study 66
Overview on novel strategies and current guidelines for hematopoietic stem cell mobilisation and collection 64
The Sorafenib plus Nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of the FLT3 and p53 status 63
Aberrant expression of HLA-DR antigen by bone marrow-derived mesenchymal stromal cells from patients affected by acute lymphoproliferative disorders 63
Ziftomenib in Relapsed or Refractory NPM1-Mutated AML 62
Isolamento e caratterizzazione immunofenotipica di cellule non-emopoietiche presenti in versamenti ascitici e pleurici di pazienti con malattie ematologiche 61
Ibrutinib: from bench side to clinical implications 60
Individual quality assessment of autografting by probability estimation for clinical endpoints: a prospective validation study from the European group for blood and marrow transplantation 58
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia 58
Growing adoption of pharmacologic maintenance therapy after allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a survey on behalf of the EBMT acute leukemia working party 57
Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients 57
Novel approaches for hematopoietic stem cell mobilisation and collection need to be assessed for qualification and validation to accomplish the proper requirements of their intended purpose 57
Allogeneic transplantation for AML aged>= 70 years. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT) 55
CD123 (Interleukin 3 receptor a chain) 55
Cytogenetic and molecular cytogenetic profile of bone marrow-derived mesenchymal stromal cells in chronic and acute lymphoproliferative disorders 54
Maimonide. Origini storiche e percorsi di umanizzazione della cura 54
Therapeutic Use of Convalescent Plasma in COVID-19 Infected Patients with Concomitant Hematological Disorders 54
Cellule staminali circolanti in pazienti con infarto miocardico 54
Issue highlights—November 2024 53
Cellule staminali circolanti in pazienti con infarto miocardico 52
Chemotherapy-based versus chemotherapy-free stem cell mobilization (± plerixafor) in multiple myeloma patients: an Italian cost-effectiveness analysis 52
In Memoriam of Riccardo Saccardi (Careggi University Hospital, Florence), eminent hematologist and a remarkable innovator in the treatment of autoimmune diseases by means of novel methodologies in HSC transplantation 52
Wide-transcriptome analysis and cellularity of bone marrow CD34+/lin- cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs. 12 months of first-line nilotinib treatment 51
MRD Assessment in Patients With Acute Myeloid Leukemia Aged ≥ 60 Years Treated With a 10‐Day Decitabine Schedule Versus Intensive Chemotherapy in the AML21 Study 51
Totale 11.187
Salva come PNG Salva come JPEG
Categoria #
all - tutte 52.124
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 52.124
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021159 0 0 0 0 0 0 0 0 0 0 23 136
2021/2022500 79 3 31 29 40 30 18 35 14 50 99 72
2022/2023932 50 69 35 61 34 37 12 149 165 132 92 96
2023/2024650 35 61 66 58 75 93 36 50 34 64 38 40
2024/20253.897 91 272 318 208 591 144 403 95 121 326 340 988
2025/20269.663 1.012 1.548 1.086 859 691 320 672 382 1.887 985 221 0
Totale 16.763